9-27-00

IFW

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON P. 2 4 2004 AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, POBOX 1450, ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

IPE XXX

PATENT

Attorney's Docket No.: 00028.08CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/749,537

Filed:

12/30/2003

Title

DELIVERY OF SEDATIVE-HYPNOTICS THROUGH AN

INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date:

SEP. 2 4 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **TRANSMITTAL FORM** (to be used for all correspondence after initial filing)

Application Number	10/749,537
Filing Date	12/30/2003
First Named Inventor	Joshua D. Rabinowitz
Art Unit	Not yet known
Examiner Name	To be assigned
Attorney Docket Number	00028.08CON

PTO/SB/21 (08-03)

Total Number of Pa	ages in This Submission		Attorney Docke	et Number	000	28.08CON	
ENCLOSURES (check all that apply)							
Extension of T	ached Reply Final vits/declaration(s)	Drawing(s) Licensing Petition Petition to Provision Change of Terminal		ion		After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below):	
Certified Copy Document(s) Response to I Incomplete Ap	Missing Parts/	Remarks Info. Discl. State Form 1449 (3 co Copy of: krefe Return Postcard	pies, 8 pages eac				
	SIGNATUR	RE OF APPLICA	NT, ATTORNEY	, OR AGENT	•		
Firm or ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 9430% Customer Number 37485 Individual name Signature							
Date	SEP. 2 4 20	004					

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the Typed or printed name Elaine C. Stracker Signature SEP. 24 2004 Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Alexandria, VA 22313-1450.

Form PTO-1 19 INFORMATION DISCLO

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 00028.08CON

Application Number: 10/749,537

Applicant:

Joshua D. RABINOWITZ et al.

Filing Date: 12/30/2003

Group Art Unit: Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Haillty			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	01/23/1990	4,895,719	Radhakrishnun et al.			
	4.	09/17/1991	5,049,389	Radhakrishnun			
	5.	02/14/1995	5,388,574	Ingebrethsen			
	6.	08/13/1996	5,544,646	Lloyd et al.			
	7.	12/09/1997	5,694,919	Rubsamen et al.			· · · · · · · · · · · · · · · · · · ·
	8.	04/07/1998	5,735,263	Rubsamen et al.			
	9.	04/14/1998	5,738,865	Baichwal et al.			
	10.	06/02/1998	5,758,637	Ivri et al.			
	11.	06/16/1998	5,767,117	Moskowitz			
 	12.	06/29/1999	5,915,378	Lloyd et al.			
	13.	08/10/1999	5,934,272	Lloyd et al.			
	14.	09/28/1999	5,957,124	Lloyd et al.			
	15.	10/05/1999	5,960,792	Lloyd et al.			
	16.	11/30/1999	5,993,805	Sutton et al.			
	17.	03/28/2000	6,041,777	Faithfull et al.			
	18.	04/18/2000	6,051,566	Bianco			
	19.	08/01/2000	6,095,134	Sievers et al.			
	20.	08/01/2000	6,095,153	Kessler et al.			
	21.	08/15/2000	6,102,036	Slutsky et al.			
	22.	06/05/2001	6,241,969	Saidi et al.			
	23.	07/03/2001	6,255,334	Sands		·	
	24.	11/06/2001	6,313,176	Ellinwood, Jr. et al.			
	25.	01/14/2003	6,506,762	Horvath et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Form PTO-1449		Docket Number: 00028.08CON	Application Number: 10/749,537	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Joshua D. RA	ABINOWITZ et al.		
	(Use several sheets if necessary)		Filing Date: 12/30/2003	Group Art Unit: Not Yet Known	
					·
ļ	126	02/04/2002			
<u> </u>	26.	02/04/2003	6,514,482	Bartus et al.	
<u> </u>	27.	07/15/2003	6,591,839	Meyer et al.	
	28.	09/06/2001	US 2001/0020147	Staniforth et al.	
ļ 	29.	03/28/2002	US 2002/0037828	Wilson et al.	
	30.	05/16/2002	US 2002/0058009	Bartus et al.	·
	31.	07/04/2002	US 2002/0086852	Cantor	
	. 32.	08/22/2002	US 2002/0112723	Schuster et al.	
	33.	11/28/2002	US 2002/0176841	Barker et al.	
	34.	01/02/2003	US 2003/0004142	Prior et al.	
	35.	02/13/2003	US2003/0032638	Kim et al.	
	36.				
		08/04/2003	10/633,876	Hale et al.	
•	37.	08/04/2003	10/633,877	Hale et al.	
	37. 38.	08/04/2003 12/30/2003	10/633,877 10/749,539	Hale et al. Rabinowitz et al.	
	37. 38. 39.	08/04/2003 12/30/2003 01/27/2004	10/633,877 10/749,539 10/766,149	Hale et al. Rabinowitz et al. Rabinowitz et al.	
-	37. 38. 39. 40.	08/04/2003 12/30/2003 01/27/2004 01/27/2004	10/633,877 10/749,539 10/766,149 10/766,279	Hale et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al.	
-	37. 38. 39. 40. 41.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566	Hale et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,647	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,647 10/767,115	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,647 10/767,115 10/768,205	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,647 10/767,115 10/768,205 10/768,220	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004 01/29/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/767,115 10/768,205 10/768,220 10/768,281	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004 01/29/2004 01/29/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,647 10/767,115 10/768,205 10/768,220 10/768,281 10/768,293	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004 01/29/2004 01/29/2004 01/29/2004 01/29/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,647 10/767,115 10/768,205 10/768,220 10/768,281 10/768,293 10/769,046	Hale et al. Rabinowitz et al.	
	37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50.	08/04/2003 12/30/2003 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/27/2004 01/28/2004 01/29/2004 01/29/2004 01/29/2004 01/30/2004 01/30/2004	10/633,877 10/749,539 10/766,149 10/766,279 10/766,566 10/766,574 10/766,634 10/766,634 10/767,115 10/768,205 10/768,220 10/768,220 10/768,293 10/769,046 10/769,051	Hale et al. Rabinowitz et al.	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Application Number: 10/749,537 Form PTO-1449 Docket Number: 00028.08CON INFORMATION DISCLOSURE CITATION Joshua D. RABINOWITZ et al. Applicant: IN AN APPLICATION (Use several sheets if necessary) Filing Date: 12/30/2003 Group Art Unit: Not Yet Known 54. 02/09/2004 10/775,583 Rabinowitz et al. 55. 02/09/2004 Rabinowitz et al. 10/775,586 56. 03/03/2004 10/791,915 Hale et al. 57. 03/03/2004 10/792,001 Rabinowitz et al. 58. 03/03/2004 10/792,012 Hale et al. 59. 03/03/2004 10/792,013 Rabinowitz et al. 60. 03/03/2004 10/792,096 Hale et al. 61. 03/03/2004 10/792,239 Hale et al. 62. 03/31/2004 Rabinowitz et al. 10/813,721 63. 03/31/2004 Rabinowitz et al. 10/813,722 64. 03/31/2004 10/814,690 Rabinowitz et al. 65. 03/31/2004 10/814,998 Rabinowitz et al. 66. 04/01/2004 10/815,527 Rabinowitz et al. 67. 04/01/2004 10/816,407 Rabinowitz et al. 68. 04/01/2004 10/816,492 Rabinowitz et al. Rabinowitz et al. 69. 04/01/2004 10/816,567 70. 08/04/2004 10/912,462 Hale et al. 01/23/2003 US 2003/0015196 Hodges et al. 72. Wensley et al. 04/03/2003 US 2003/0062042 73. 11/13/2003 US 2003/0209240 Hale et al. 74. 01/02/2003 Rabinowitz et al. US 2003/0000518 75. 01/09/2003 US 2003/0005924 Rabinowitz et al. 76. 01/09/2003 Hale et al. US 2003/0005925 77. 01/09/2003 US 2003/0007933 Rabinowitz et al. .78. 01/09/2003 US 2003/0007934 Rabinowitz et al. 79. 01/16/2003 US 2003/0012737 Rabinowitz et al. 80. 01/16/2003 US 2003/0012738 Rabinowitz et al. 81. 1/16/2003 US 2003/0012740 Rabinowitz et al. 82. 01/23/2003 US 2003/0015189 Rabinowitz et al. 83. 01/23/2003 US 2003/0015190 Rabinowitz et al. DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number: 00028.08CON Application Number: 10/749		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Joshua D. R.	ABINOWITZ et al.	
	(Use several sheets if	necessary)	Filing Date: 12/30/2003	Group Art Unit: Not Yet Known
			· · · · · · · · · · · · · · · · · · ·	<u></u>
		·		
84		US 2003/0017114	Rabinowitz et al.	
85		US 2003/0017115	Rabinowitz et al.	
86	. 01/23/2003	US 2003/0017116	Rabinowitz et al.	
87	. 01/23/2003	US 2003/0017117	Rabinowitz et al.	
88	. 01/23/2003	US 2003/0017118	Rabinowitz et al.	
89	. 01/23/2003	US 2003/0017119	Rabinowitz et al.	
90	. 01/23/2003	US 2003/0017120	Rabinowitz et al.	
91	. 1/30/2003	US 2003/0021753	Rabinowitz et al.	
92	. 01/30/2003	US 2003/0021754	Rabinowitz et al.	
93	. 01/30/2003	US 2003/0021755	Hale et al.	
94	. 02/20/2003	US 2003/0035776	Hodges et al.	
95	. 05/15/2003	US 2003/0091511	Rabinowitz et al.	·
96	. 05/27/2004	US 2004/010148	Hale et al.	
97	. 07/31/2003	US 2003/0138382	Rabinowitz	
98	. 11/06/2003	US 2003/0206869	Rabinowitz et al.	
99	. 01/15/2004	US 2004/0009128	Rabinowitz et al.	
100.	05/20/2004	US 2004/0096402	Hodges et al.	
101.	05/27/2004	US 2004/0099269	Hale et al.	
102.	06/03/2004	US 2004/0105818	Hale et al.	
103.	06/03/2004	US 2004/0105819	Hale et al.	
104.	07/01/2004	US 2004/0126326	Rabinowitz et al.	
105.		US 2004/0126327	Rabinowitz et al.	
106.		US 2004/0126328	Rabinowitz et al.	
107.		US 2004/0126329	Rabinowitz et al.	
108.	07/01/2004	US 2004/0127481	Rabinowitz et al.	
109.		US 2004/0127490	Rabinowitz et al.	
110.		US 2004/0156788	Rabinowitz et al.	
111.	- 	US 2004/0156789	Rabinowitz et al.	
112.		US 2004/0156790	Rabinowitz et al.	
113.		US 2004/0156791	Rabinowitz et al.	
EXAMINER			DATE CONSIDERED:	
EVVIANTINE	∖.		Ditte Condidention.	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

		5.000.000	
Form PTO-1449	Docket Number: 00028.08CON	Application Number: 10/749,537	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.		
(Use several sheets if necessary)	Filing Date: 12/30/2003	Group Art Unit: Not Yet Known	
	1.		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	114.	03/14/1990	EP 0 358 114	Europe			
	115.	07/03/2001	EP 1 080 720	Europe		·	
	116.	08/29/2001	EP 0 606 486	Europe			-
	117.	03/22/1990	WO 90/02737	WIPO			
	118.	06/13/1991	WO 91/07947	WIPO			
	119.	04/11/1996	WO 96/09846	WIPO			
	120.	05/09/1996	WO 96/13161	WIPO			
•	121.	05/09/1996	WO 96/13290	WIPO			
	122.	05/09/1996	WO 96/13291	WIPO			
-	123.	05/09/1996	WO 96/13292	WIPO			
	124.	10/03/1996	WO 96/30068	WIPO			
	125.	08/07/1997	WO 97/27804	WIPO			
	126.	05/28/1998	WO 98/22170	WIPO			
	127.	07/23/1998	WO 98/31346	WIPO			
	128.	08/27/1998	WO 98/36651	WIPO			
	129.	04/08/1999	WO 99/16419	WIPO			
	130.	12/16/1999	WO 99/64094	WIPO .			
	131.	01/06/2000	WO 00/00176	WIPO			
	132.	01/06/2000	WO 00/00215	WIPO			
	133.	05/18/2000	WO 00/27363	WIPO			
	134.	05/25/2000	WO 00/29053	WIPO			
	135.	08/17/2000	WO 00/47203	WIPO			
	136.	11/02/2000	WO 00/64940	WIPO			
	137.	11/09/2000	WO 00/66084	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

DATE CONSIDERED:			
·			
•			
WIPO	<u> </u>		
WIPO			
Filing Date: 12/30/2003	Group Art Unit: Not Yet Known		
Applicant: Joshua D. RABINOWITZ et al.			
Applicant: Inchus D. D.A.F.	INOWITZ et al		
Docket Number: 00028.08CON Application Number: 10/74			
	Applicant: Joshua D. RAE Filing Date: 12/30/2003 WIPO WIPO WIPO WIPO WIPO WIPO WIPO WIP		

Form PTC	-1449		Docket Number: 00028.08CON	Application Number: 10/749,537		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant: Joshua D. RABINOWITZ et al.			
		se several sheets if necessary)	Filing Date: 12/30/2003	Group Art Unit: Not Yet Known		
	_					
		OTHER DOCUMENTS	(including author, title, Date, Perti	nent Pages, Etc.)		
Examiner Initials	Ref. No.	Title				
	145.	Bennett, R.L. et al. (1981). "Patient-C Relief," Annual Surg. 195(6):700-705		ncept of Postoperative Pain		
	146.	Carroll, M.E. et al. (1990), "Cocaine-leffects," Psychopharmacology (Berl).		s: reinforcing and physiological		
·	147.	Clark, A. and Byron, P. (1986). "Depersize," Z. Erkrank. 166:13-24.	endence of Pulmonary Absorption	on Kinetics on Aerosol Particle		
	148.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," <i>American Physiological Society</i> . 966-974.				
	149.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Physiol 32(5):591-600.				
-	150.	Dershwitz, M., M.D., et al. (September 2000). "Pharmacokinetics and Pharmacodynamics of Inhale versus Intravenous Morphine in Healthy Volunteers," <i>Anesthesiology</i> . 93(3): 619-628.				
-	151.	Finlay, W.H. (2001). "The Mechanics of Inhaled Pharmaceutical Aerosols", Academic Press: San Diego Formula 2.39. pp.3-14 (Table of Contents). pp. v-viii.				
	152.	Gonda,I. (1991). "Particle Deposition in the Human Respiratory Tract," Chapter 176, <u>The Lung: Scientific Foundations</u> . Crystal R.G. and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294.				
	153.	Hatsukami D, et al. (May 1990) "A m humans." Pharmacology Biochemistry		ses of smoked cocaine-base to		
154. Heyder, J. et al. (1986). "Deposition of Particles in the Human Respiratory Tract in the Size Ra 0.005-15 μm," J. Aerosol Sci. 17(5):811-822.						
	155.	5. Huizer, H., "Analytical studies on illicit heron. V. Efficacy of volatilization during heroin smoking. Pharmaceutisch Weekblad Scientific Edition (1987). 9(4):203-211.				
	156.	Hurt, R.D., MD and Robertson, C.R., PhD, (October 1998). "Prying Open the Door to the Tobacc Industry's Secrets About Nicotine: The Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.				
	157.	7. Lichtman, A.H. et al. (1996). "Inhalation Exposure to Volatilized Opioids Produces Antinocicept in Mice," Journal of Pharmacology and Experimental Therapeutics. 279(1):69-76.				
	158.	Martin, B.R. and Lue, L.P. (May/June Analytical Toxicology 13:158-162.	e 1989). "Pyrolysis and Volatiliz	zation of Cocaine," Journal of		
	159.	Mattox, A.J. and Carroll, M.E., (1996 Psychopharmacology, 125:195-201.). "Smoked heroin self-adminis	tration in rhesus monkeys,"		
ЕХАМГ	NER:		DATE CONSIDERED:			
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-144	9	Docket Number: 00028.08CON Application Number: 10/749,537			
	TION DISCLOSURE CITATION N AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.			
	(Use several sheets if necessary)	Filing Date: 12/30/2003	Group Art Unit: Not Yet Known		
160.	Meng, Y. et al. "Inhalation Studies W 173:201-224.	ith Drugs of Abuse, "NIDA Re	esearch Monograph, (1997)		
161.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," Drug and Alcoh	gical effects of methamphetam nol Dependence. 53:111-120.	ne and other stimulants via		
162.	Office Action mailed 8/13/2003 for U BENZODIAZEPINES THROUGH A	S application 10/153,313 filed N INHALATION ROUTE".	5/21/2002 "DELIVERY OF		
163.	Pankow, J.F. et al. (1997). "Conversion Free-Base Form Through the Action of	on of Nicotine in Tobacco Smoot Gaseous Ammonia," Envron	ke to Its Volatile and Available . Sci. Technol. 31:2428-2433.		
164.	Pankow, J. (March 2000). ACS Confe	erence-San Francisco-3/26/00.	Chemistry of Tobacco Smoke.		
165.	Seeman, J. et al. (1999). "The Form o Nicotine Acid Salts to Nicotine in the	of Nicotine in Tobacco. Thermal Transfer of Nicotine and the Gas Phase, "J. Agric. Food Chem. 47(12):5133-5145.			
166.					
167.	Vapotronics, Inc. (1998) located at ht June 5, 2000).	tp://www.vapotronics.com.au/l	oanner.htm., 11 pages, (visited on		
168.	Ward, M.E. MD, et al. (December 199) Administration from a Novel Aerosol 62(6):596-609.	77). "Morphine Pharmacokinet Delivery System," Clinical Ph	ics after Pulmonary narmacology & Therapeutics		
169.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and Description of Biochemistry & Behavior. 55(2):237-	emonstration of Their Biologic	of Cocaine Base and Its al Activity." Pharmacology		
					
			·		
	·	·			
		•			
EXAMINER:		DATE CONSIDERED:			
EXAMINER: I	nitial if citation considered, whether or not the citat	tion conforms with MPEP 609. Draw	a line through the citation if not in		

conformance and not considered. Include a copy of this form with next communication to applicant.